Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
Aclaris Therapeutics, Inc.
ACRS
Mkt Cap
$482.4M
Volume
2.15M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
ACRS
AC
Aclaris Therapeutics, Inc.
ACRS
News
·
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Mkt Cap
$513.7M
Volume
2.15M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aclaris Therapeutics announced that CEO Dr. Neal Walker will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026. The clinical-stage biopharmaceutical company, which focuses on developing treatments for immuno-inflammatory diseases, will provide a live and archived webcast of the event on its website.
GlobeNewswire Inc. · Sep 3, 2026
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Aclaris Therapeutics announced that results from its Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, will be presented as an ePoster at the 2026 AAD Annual Meeting in Denver. The poster will include previously unreported results from the open-label trial in patients with moderate-to-severe atopic dermatitis.
GlobeNewswire Inc. · Mar 20, 2026
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
Aclaris Therapeutics announced the initiation of a Phase 1b proof-of-concept trial for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in asthma patients. This follows the recent start of a similar trial in atopic dermatitis. The company expects to report top-line results from both trials in the second half of 2026 and plans to initiate a Phase 2b program shortly thereafter.
GlobeNewswire Inc. · Feb 24, 2026
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aclaris Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, with CEO Dr. Neal Walker presenting a fireside chat.
GlobeNewswire Inc. · Nov 25, 2025
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aclaris Therapeutics will present additional results from its Phase 2a trial of ATI-2138, an investigational oral drug targeting ITK and JAK3, at the 2025 European Academy of Dermatology and Venereology Congress in Paris.
GlobeNewswire Inc. · Sep 9, 2025
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
Aclaris Therapeutics will participate in two healthcare conferences in September 2025, with CEO Dr. Neal Walker presenting at the Cantor Global Healthcare Conference and H.C. Wainwright Global Investment Conference.
GlobeNewswire Inc. · Aug 27, 2025
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results and provided a corporate update. The company's CEO and senior leadership team will participate in a virtual fireside chat.
GlobeNewswire Inc. · May 9, 2025
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, has appointed Jesse Hall, M.D. as its new Chief Medical Officer. Dr. Hall's extensive experience in areas like immunology and antibody development will be crucial in leading Aclaris' clinical strategy for its portfolio of immuno-inflammatory product candidates.
GlobeNewswire Inc. · Apr 29, 2025
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight
The article discusses the robust pipeline of JAK inhibitors, with over 50 key pharmaceutical companies actively working on developing new drugs in this therapeutic segment. The pipeline includes promising JAK inhibitors in various stages of clinical trials, targeting a range of autoimmune disorders and cancer.
GlobeNewswire Inc. · Mar 3, 2025
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced that members of its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference.
GlobeNewswire Inc. · Sep 10, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AC
ACRS
Aclaris Therapeutics, Inc.
Buy
Sell
Market
Limit
Soon
ACRS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ACRS yet.
Related Tickers
Earnings